JAN 13, 2022 3:00 AM PST

An Arthritis Drug Combats Chemoresistance in Pancreatic Cancer

WRITTEN BY: Katie Kokolus

The American Cancer Society estimates the lifetime risk of pancreatic cancer at about 1 in 64. Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of pancreatic cancers. PDAC is the fourth leading cancer-related cause of death, and 5-year survival from is only 8%. Thus, novel strategies to treat this aggressive disease are expressly needed.

Standard treatment for PDAC involves a combination of multiple chemotherapies; however, most patients quickly develop resistance, known as chemoresistance. A new study published in Science Translational Medicine identified a mechanism underlying chemoresistance which could provide valuable information to inform drug and treatment development. 

The study investigated chemoresistance to FIRNOX, a chemotherapy regimen consisting of 5-fluorouracilirinotecan, and oxaliplatin. FIRNOX is commonly used to treat PDAC patients. The authors found that FIRNOX activated Hsp27, a protein that aids in the survival of PDAC cells. The researchers inhibited HSP27 signaling in PDAC cells resulting in increased cell death, known as apoptosis, following FIRINOX treatment.  Further, the study demonstrated that the MAPK activated protein kinase 2 (MK2) pathway regulated Hsp27 expression. Targeting MK2 hindered Hsp27 activation, thus increasing apoptosis in PDAC cells.  

Further, the study demonstrated that the MAPK activated protein kinase 2 (MK2) pathway regulated Hsp27 expression.  Targeting MK2 hindered Hsp27 activation thus increasing apoptosis in PDAC cells. 

Next, the study utilized an in vivo mouse model of PDAC to investigate the efficacy of the MK2 inhibiting drug, ATI-450, which is being investigated to treat rheumatoid arthritis.  Treatment of tumor-bearing mice with ATI-450 resulted in reduced PDAC progression.  When researchers administered ATI-450 combined with FIRINOX, tumor-bearing mice exhibited significantly extended survival.  Notably, the MK2 inhibitor and chemotherapy combination did not induce any additional toxicities in the animals. 

Finally, in a translational approach, the study investigated the association between MK2 expression and survival in PDAC patients.  Using surgical biopsies from 130 PDAC patients, the researchers found that high MK2 expression correlated to poor survival. 

In summary, the study identified MK2 induction of Hsp27 as a protumor mechanism protecting PDAC cells from FIRINOX.  The authors suggest that MK2 could serve as a viable therapeutic target for PDAC treatment, particularly to enhance chemotherapy-induced apoptosis. 

 

Sources: Int J Mol Sci, Radiation Oncology, Science Translational Medicine, Clin Pharmacol, ClinicalTrials.gov

About the Author
  • PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
SEP 09, 2021
Cancer
Can a Mole Fight Melanoma?
SEP 09, 2021
Can a Mole Fight Melanoma?
About 30% of melanoma cases arise from an existing nevus.  More commonly known as moles, Nevi are skin growths that ...
SEP 16, 2021
Technology
Scientists Create Tiny Replicas Of The Pancreas To Study New Drugs
SEP 16, 2021
Scientists Create Tiny Replicas Of The Pancreas To Study New Drugs
Pancreatic cancer it’s often hard to diagnose in its early stages, resulting in patients having more advanced canc ...
SEP 27, 2021
Cell & Molecular Biology
Optical Imaging in Tissue with Near-Infrared Dyes
SEP 27, 2021
Optical Imaging in Tissue with Near-Infrared Dyes
Optical Imaging in Tissue with Near-Infrared Dyes Written By Christopher Pratt, PhD   Go Long to See Deeper Imaging ...
OCT 14, 2021
Immunology
'Bio-Betters' Form the Next Wave of Cancer Therapies
OCT 14, 2021
'Bio-Betters' Form the Next Wave of Cancer Therapies
  Antibodies are blood proteins with highly specialized functions: to recognize and eliminate bacteria, viruses, an ...
NOV 29, 2021
Microbiology
How the Hepatitis B Virus Promotes Liver Cancer Development
NOV 29, 2021
How the Hepatitis B Virus Promotes Liver Cancer Development
It's estimated that about 240 million people worldwide have an HBV infection. Hepatitis B infections are linked to t ...
JAN 20, 2022
Cancer
New Links Between Prostate Cancer Therapy and Depression
JAN 20, 2022
New Links Between Prostate Cancer Therapy and Depression
According to 2021 estimates, prostate cancer will account for more than a quarter of the cancer diagnoses and over 10% o ...
Loading Comments...